Results 41 to 50 of about 3,095,271 (376)
Amniotic fluid embolism pathophysiology suggests the new diagnostic armamentarium: β-tryptase and complement fractions C3-C4 are the indispensable working tools [PDF]
Amniotic fluid embolism (AFE) is an uncommon obstetric condition involving pregnant women during labor or in the initial stages after delivery. Its incidence is estimated to be around 5.5 cases per 100,000 deliveries.
Busardo', FRANCESCO PAOLO +3 more
core +2 more sources
Impaired control of the contact system in hereditary angioedema with normal C1‐inhibitor
Hereditary angioedema (HAE) comprises HAE with C1‐inhibitor deficiency (C1‐INH‐HAE) and HAE with normal C1‐INH activity (nl‐C1‐INH‐HAE), due to mutations in factor XII (FXII‐HAE), plasminogen (PLG‐HAE), angiopoietin 1 (ANGPT1‐HAE), kininogen 1 genes ...
M. Bova +15 more
semanticscholar +1 more source
Background. Hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH) is caused by dysfunctional C1-INH protein due to mutations in the SERPING1 gene encoding C1-INH.
Ezgi Topyıldız +4 more
doaj +1 more source
C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis. [PDF]
Grover SP +16 more
europepmc +2 more sources
Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage [PDF]
Hypoxic-ischemic encephalopathy (HIE) is a clinical condition in the neonate, resulting from oxygen deprivation around the time of birth. HIE affects 1-5/1000 live births worldwide and is associated with the development of neurological deficits ...
Hristova, M, Rocha-Ferreira, E
core +1 more source
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
Patients with hereditary angioedema with C1 inhibitor deficiency or dysfunction have burdensome recurrent angioedema attacks. The safety, efficacy, and health‐related quality of life (HRQoL) outcomes of C1 inhibitor (C1‐INH) prophylaxis (intravenously ...
E. Aygören‐Pürsün +11 more
semanticscholar +1 more source
N- and O-glycosylation Analysis of Human C1-inhibitor Reveals Extensive Mucin-type O-Glycosylation
Human C1-inhibitor (C1-Inh) is a serine protease inhibitor and the major regulator of the contact activation pathway as well as the classical and lectin complement pathways. It is known to be a highly glycosylated plasma glycoprotein.
K. Stavenhagen +10 more
semanticscholar +1 more source
Whooping cough, or pertussis, is a contagious disease of the respiratory tract that is re-emerging worldwide despite high vaccination coverage. The causative agent of this disease is the Gram-negative Bordetella pertussis. Knowledge on complement evasion
E. S. Hovingh +5 more
semanticscholar +1 more source
Expression of platelet C1 inhibitor [PDF]
Abstract Human platelets contain a pool of C1 inhibitor (C1 INH) distinct from that in plasma. Twelve normal platelet samples washed by centrifugation had a mean platelet C1 INH antigen level of 19.3 +/- 2.8 ng (mean +/- SEM) per 10(8) platelets. These values contrast with the mean +/- SEM platelet C1 INH antigen level of 6.1 +/- 0.9 per
A H, Schmaier +4 more
openaire +3 more sources
BackgroundHereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is characterized by recurrent edema of unpredictable frequency and severity. Stress, anxiety, and low mood are among the triggering factors most frequently reported.
Livia Savarese +18 more
semanticscholar +1 more source

